For example, the G2032R mutation in the ROS1 kinase domain confers resistance to Crizotinib in lung adenocarcinoma (LADC) by disrupting its inhibition of ALK, ROS1, and MET tyrosine kinases[41]. The gene discussed is ROS1; the disease is lung adenocarcinoma.